Advertisement
IMVT vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and SYRE is a Hold.
IMVT in upward trend: price rose above 50-day moving average on November 09, 2026
IMVT moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMVT as a result. In 75 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.
Following a +16.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
IMVT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.575) is normal, around the industry mean (3.498). P/E Ratio (-10.865) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 50 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SYRE's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for SYRE moved out of overbought territory on November 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 24 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
SYRE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 65 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +12.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 261 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 148 of 174 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.592) is normal, around the industry mean (3.498). P/E Ratio (-54.111) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMVT | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 50 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 41 | 34 | |
P/E GROWTH RATING 1..100 | 18 | 54 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as IMVT (31) in the null industry. This means that SYRE’s stock grew similarly to IMVT’s over the last 12 months.
IMVT's Profit vs Risk Rating (50) in the null industry is somewhat better than the same rating for SYRE (100) in the Pharmaceuticals Major industry. This means that IMVT’s stock grew somewhat faster than SYRE’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as IMVT (98) in the null industry. This means that SYRE’s stock grew similarly to IMVT’s over the last 12 months.
SYRE's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as IMVT (41) in the null industry. This means that SYRE’s stock grew similarly to IMVT’s over the last 12 months.
IMVT's P/E Growth Rating (18) in the null industry is somewhat better than the same rating for SYRE (54) in the Pharmaceuticals Major industry. This means that IMVT’s stock grew somewhat faster than SYRE’s over the last 12 months.
| IMVT | SYRE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 70% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 88% |
| Advances ODDS (%) | 2 days ago 77% | 3 days ago 87% |
| Declines ODDS (%) | 10 days ago 81% | 7 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMVT’s FA Score shows that 2 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
- IMVT’s FA Score: 2 green, 3 red.
- SYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMVT’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).
- IMVT’s TA Score: 4 bullish, 5 bearish.
- SYRE’s TA Score: 6 bullish, 4 bearish.
Price Growth
IMVT (@Biotechnology) experienced а +22.97% price change this week, while SYRE (@Biotechnology) price change was +5.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
IMVT is expected to report earnings on Feb 16, 2027.
SYRE is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMVT and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +1.59% | ||
| ROIV - IMVT | 65% Loosely correlated | +1.28% | ||
| LXEO - IMVT | 50% Loosely correlated | -2.55% | ||
| XNCR - IMVT | 48% Loosely correlated | +2.07% | ||
| KURA - IMVT | 48% Loosely correlated | N/A | ||
| TSHA - IMVT | 47% Loosely correlated | -2.17% | ||
More | ||||
SYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | -4.15% | ||
| ORKA - SYRE | 51% Loosely correlated | +4.72% | ||
| IMVT - SYRE | 46% Loosely correlated | +1.59% | ||
| PHVS - SYRE | 46% Loosely correlated | -1.39% | ||
| TSHA - SYRE | 45% Loosely correlated | -2.17% | ||
| BEAM - SYRE | 45% Loosely correlated | -6.92% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RWM | 14.30 | 0.10 | +0.70% |
| ProShares Short Russell2000 (RWM) | |||
| KPDD | 4.86 | N/A | N/A |
| KraneShares 2x Long PDD Daily ETF (KPDD) | |||
| XFEB | 38.32 | -0.02 | -0.05% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - February (XFEB) | |||
| XLU | 43.73 | -0.06 | -0.14% |
| State Street Utilities Select Sector SPDR ETF (XLU) | |||
| RMT | 13.19 | -0.07 | -0.53% |
| Royce Micro-Cap Trust | |||